CL2020002876A1 - Infectious Bronchitis Vaccine (Divisional Application No. 201803420) - Google Patents

Infectious Bronchitis Vaccine (Divisional Application No. 201803420)

Info

Publication number
CL2020002876A1
CL2020002876A1 CL2020002876A CL2020002876A CL2020002876A1 CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1 CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1
Authority
CL
Chile
Prior art keywords
divisional application
infectious bronchitis
bronchitis vaccine
vaccine
component
Prior art date
Application number
CL2020002876A
Other languages
Spanish (es)
Inventor
Freitas Carla Maria Batista De
Santos Maria Carolina Ferreira Dos
Paul Joseph Dominowski
Harmen Jacob Geerligs
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2020002876A1 publication Critical patent/CL2020002876A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una vacuna que comprende un componente de antígeno y un componente adyuvante, en donde el componente adyuvante comprende un oligonucleótido inmunoestimulante y una emulsión de agua-en-aceite (W/O), donde el componente antigénico comprende un virus IBD inactivado, y donde el oligonucleótido inmunoestimulante comprende la SEQ ID NO: 8 en una cantidad de 2,5 a 20 µg por dosis.A vaccine comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises an immunostimulating oligonucleotide and a water-in-oil (W / O) emulsion, wherein the antigen component comprises an inactivated IBD virus, and where the immunostimulatory oligonucleotide comprises SEQ ID NO: 8 in an amount of 2.5 to 20 µg per dose.

CL2020002876A 2016-06-02 2020-11-06 Infectious Bronchitis Vaccine (Divisional Application No. 201803420) CL2020002876A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344598P 2016-06-02 2016-06-02
US201662365419P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
CL2020002876A1 true CL2020002876A1 (en) 2021-05-07

Family

ID=59215993

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (en) 2016-06-02 2018-11-30 Vaccine against infectious bronchitis.
CL2020002876A CL2020002876A1 (en) 2016-06-02 2020-11-06 Infectious Bronchitis Vaccine (Divisional Application No. 201803420)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (en) 2016-06-02 2018-11-30 Vaccine against infectious bronchitis.

Country Status (15)

Country Link
US (3) US11103573B2 (en)
EP (1) EP3463446A1 (en)
JP (3) JP7659367B2 (en)
KR (6) KR20220100725A (en)
CN (1) CN109152829A (en)
AU (1) AU2017274332B2 (en)
BR (1) BR112018075033A2 (en)
CA (2) CA3025524C (en)
CL (2) CL2018003420A1 (en)
CO (1) CO2018012905A2 (en)
MX (3) MX2018014857A (en)
PH (1) PH12018502525A1 (en)
UA (1) UA126562C2 (en)
WO (1) WO2017210244A1 (en)
ZA (3) ZA201807477B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303252A (en) * 2020-02-17 2020-06-19 青岛易邦生物工程有限公司 Purification method for large-scale production of embryotoxin antigen
TWI911572B (en) * 2022-10-04 2026-01-11 美商碩騰服務有限責任公司 Poultry vaccines and methods of protecting poultry

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1357151A1 (en) 2002-04-26 2003-10-29 ATOFINA Research Improved processing of bimodal polymers
DE602004019971D1 (en) * 2003-12-23 2009-04-23 Intervet Int Bv COMBINATION VACCINE FOR POULTRY
CA2557844C (en) * 2004-03-12 2016-06-21 Wyeth Infectious bursal disease virus antigenic isolates and vaccines
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
WO2009156960A2 (en) 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
AR072976A1 (en) 2008-08-08 2010-10-06 Wyeth Corp ISOLATED INFECTIOUS BRONCHITIS (IB) VIRUSES, VACCINE COMPOSITION AND METHOD TO PREPARE AN INFECTIOUS BRONCHITIS (IB) VIRUS ATTACHED LIVE
CN101721698B (en) 2008-10-24 2014-04-02 法罗斯疫苗公司 Anti-foot-and-mouth disease vaccine composition and its preparation and application
WO2010067262A1 (en) * 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
CN102038949A (en) * 2010-12-29 2011-05-04 青岛易邦生物工程有限公司 Method for producing newcastle disease, infectious bronchitis, egg drop syndrome and avian influenza (H9 subtype) combined inactivated vaccine
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
PT3275507T (en) 2011-04-18 2020-05-20 Univ Georgia Vaccine delivery method
HUE051277T2 (en) 2012-11-16 2021-03-01 United Biomedical Inc Synthetic peptide-based emergency vaccine against foot and mouth disease (fmd)
EP2996719B1 (en) * 2013-05-14 2019-06-26 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
UA121200C2 (en) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс OIL-BASED ADJUSTANT

Also Published As

Publication number Publication date
NZ788650A (en) 2025-08-29
MX2022012910A (en) 2022-11-14
US20250295752A1 (en) 2025-09-25
KR102893877B1 (en) 2025-12-03
JP2025041829A (en) 2025-03-26
AU2017274332B2 (en) 2024-06-27
PH12018502525A1 (en) 2019-10-21
KR20180129926A (en) 2018-12-05
BR112018075033A2 (en) 2019-03-26
EP3463446A1 (en) 2019-04-10
KR20220100725A (en) 2022-07-15
JP7679340B2 (en) 2025-05-19
KR20240141211A (en) 2024-09-25
ZA202204980B (en) 2022-09-28
US20190240315A1 (en) 2019-08-08
CA3025524C (en) 2023-03-07
US20220175911A1 (en) 2022-06-09
JP2019517526A (en) 2019-06-24
CL2018003420A1 (en) 2019-01-18
CA3025524A1 (en) 2017-12-07
MX2018014857A (en) 2019-03-07
NZ788649A (en) 2025-05-30
RU2018142329A3 (en) 2020-09-01
NZ748375A (en) 2024-07-26
KR20210068602A (en) 2021-06-09
CN109152829A (en) 2019-01-04
US11103573B2 (en) 2021-08-31
KR20220064417A (en) 2022-05-18
RU2018142329A (en) 2020-06-01
CO2018012905A2 (en) 2018-12-14
UA126562C2 (en) 2022-11-02
KR20210068601A (en) 2021-06-09
MX2022007212A (en) 2022-07-12
ZA201807477B (en) 2023-06-28
AU2017274332A1 (en) 2018-11-22
CA3175832A1 (en) 2017-12-07
ZA202204979B (en) 2022-09-28
WO2017210244A1 (en) 2017-12-07
US12171825B2 (en) 2024-12-24
RU2021117820A (en) 2021-07-07
JP2023002541A (en) 2023-01-10
JP7659367B2 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
Baz et al. H5N1 vaccines in humans
PH12019501766A1 (en) Porcine coronavirus vaccines
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
AR127585A1 (en) RESPIRATORY SYNCYCIAL VIRUS RNA VACCINE
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
MX2016012845A (en) VACCINE AGAINST THE VIRUS OF THE PORCINE EPIDEMIC DIARRHEA.
CO2019011548A2 (en) Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogenic antigens
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
MX388128B (en) COMBINED VACCINE FOR PIGS.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
MX391930B (en) FOOT-AND-MOUTH DISEASE VACCINE.
MX386606B (en) THE USE OF A VACCINE FOR THE PREVENTION OF SWINE EPIDEMIC DIARRHEA.
EA201001478A1 (en) VACCINE
WO2020012428A8 (en) New vaccines against avian reoviruses
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
AR097029A1 (en) ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
UY38933A (en) CHICUNGUÑA VIRUS-TYPE PARTICULATE VACCINE AND METHODS FOR ITS USE
UY36208A (en) "MODIFIED BACTERIA FOR IMPROVED VACCINES AGAINST BRUCELOSIS".
MX2022012910A (en) Vaccine against infectious bronchitis.
MX2012002630A (en) IMMUNIZATION REGIME FOR SENSITIZATION-REINFORCEMENT HETEROLOGY AGAINST THE BLUE LANGUAGE VIRUS.
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection
AR125960A2 (en) VACCINE FOR USE IN POULTRY AGAINST INFECTIOUS BURSITIS
AR108664A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS